pre-IPO PHARMA

COMPANY OVERVIEW

Breath is a clinical stage biopharmaceutical company specializing in advanced and first-in-class inhalation therapies for severe respiratory diseases with high unmet medical need. For its clinical development, the Company is using new proprietary drug formulations optimized for inhaled administration with exclusively licensed, high performance nebulizers. Breath is focusing on integrated therapy solutions in the interaction between diagnostic, therapy and eHealth therapy monitoring.


LOCATION

  • München, , Germany
  • Boston, MA, USA

  • THERAPEUTIC AREAS

  • Rare Diseases
  • Respiratory Disease

  • WEBSITE

    https://breath-therapeutics.com/


    CAREER WEBSITE

    https://careers@breath-therapeutics.com.


    SOCIAL MEDIA


    INVESTORS

    gimv glide-healthcare sofinnova-partners


    PRESS RELEASES


    Feb 20, 2020

    Breath Therapeutics, a Zambon company, initiates BOSTON-3 and BOSTON-4, two additional clinical studies for the treatment of bronchiolitis obliterans syndrome (BOS)


    Oct 17, 2019

    Breath Therapeutics, a Zambon company, announces presentations at upcoming scientific conferences


    Jul 25, 2019

    Sofinnova Partners Announces the Sale of Breath Therapeutics to Zambon


    Jul 25, 2019

    Zambon Completes Transformational Acquisition of Breath Therapeutics


    Mar 26, 2019

    Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome


    For More Press Releases


    Google Analytics Alternative